Gerrard et al. demonstrated that inhibiting UGCG sensitized CLL cells to active agents used in CLL such as fludarabine and chlorambucil, suggesting a potential role for UGCG inhibition in enhancing the efficacy of conventional chemotherapy [14]. This evidence concerns the gene UGCG and B-cell chronic lymphocytic leukemia.